AKT1 and malignant colon neoplasm: For instance, we have found NSC49L to be effective against colon cancer through the activation of PP2Ac and subsequently decreasing the AKT1/mTOR/4E-BP1 axis and p21 translation in FOLFOX-resistant colon cancer cells [70].